Welcome Guest   |   Log In

About ViiV Healthcare

The ViiV Healthcare Mission: Narrow Focus, Broad Access

In 2009, Pfizer and GlaxoSmithKline partnered to form ViiV Healthcare, a global specialist company 100% focused on HIV, to allow a deeper dive into research and to improve the rate of securing safe and effective therapies for people living with HIV. Following a long-term collaboration on the joint development of several novel integrase inhibitors, we were joined by Shionogi in 2012. In 2012, the ViiV Healthcare Diagnostic Resource Center went live to give healthcare professionals current information and direct online access to diagnostic programs supported by ViiV Healthcare.

Diagnostic tests can help provide information necessary to evaluate treatment options.1 ViiV Healthcare believes identifying appropriate patients for treatment helps deliver on the goal of personalized medicine, getting the right drug and dosage to the right patient at the right time.

As part of our ongoing commitment to the advancement of HIV care and treatment, ViiV Healthcare continues to offer the
HLA-AWARE™ Program, which facilitates patient access to screening for the HLA-B*5701 allele. Test analysis is performed by LabCorp® or Quest Diagnostics. These labs invoice ViiV Healthcare directly.

ViiV Healthcare extends partnerships into the HIV community in an ongoing commitment to healthcare professionals and their patients and to the overall advancement of HIV care and treatment. We will continue to support the evolution of diagnostic tests to ensure the availability of routine testing options that are accessible, affordable, and accurate.

To learn more, visit ViiV Healthcare online.